ArticleFolia microbiologica2003
Human tumor cells are selectively inhibited by colicins.
Article in Folia microbiologica, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 110 citations in OpenAlex.
- Article
- Computational and Structure-Guided engineering of colicin E1 and E2 for EMT -driven cadherin selectivity in cancer.Journal, genetic engineering & biotechnology · 2026Article
- Evaluation of skin cancer prevention properties of probiotics.Genes & nutrition · 2025Review
- The potential of bacteriocins and bacteriophages to control bacterial disease of crops with a focus onJournal of the Royal Society of New Zealand · 2025Review
- Escherichia coli on colorectal cancer: A two-edged sword.Microbial biotechnology · 2024Review
- Bacteriocins in Cancer Treatment: Mechanisms and Clinical Potentials.Biomolecules · 2024Review
- Two Recombinant Bacteriocins, Rhamnosin and Lysostaphin, Show Synergistic Anticancer Activity Against Gemcitabine-Resistant Cholangiocarcinoma Cell Lines.Probiotics and antimicrobial proteins · 2024Article
- Redefining bioactive small molecules from microbial metabolites as revolutionary anticancer agents.Cancer gene therapy · 2024Review
- Microbiome and cancer: from mechanistic implications in disease progression and treatment to development of novel antitumoral strategies.Frontiers in immunology · 2024Review
- Biotechnological Applications of Probiotics: A Multifarious Weapon to Disease and Metabolic Abnormality.Probiotics and antimicrobial proteins · 2022Review
- Review
- Beneficial features of pediococcus: from starter cultures and inhibitory activities to probiotic benefits.World journal of microbiology & biotechnology · 2022Review
- Colicins and Microcins Produced byInternational journal of environmental research and public health · 2022Review
- Do Bacteria Provide an Alternative to Cancer Treatment and What Role Does Lactic Acid Bacteria Play?Microorganisms · 2022Review
- Molecular identification of lactic acid bacteria SR6 strain and evaluation of its activity as an anticancer in T47D cell line.Veterinary world · 2022Article
- Bacteria-Mediated Modulatory Strategies for Colorectal Cancer Treatment.Biomedicines · 2022Review
- Article
- Heterologous overexpression and preliminary antimicrobial activity test of salmocin M, a novel colicin M-like bacteriocin against Salmonella sp.Archives of microbiology · 2022Article
- An Update on the Effectiveness of Probiotics in the Prevention and Treatment of Cancer.Life (Basel, Switzerland) · 2022Review
- The Use of Bacteria in Cancer Treatment: A Review from the Perspective of Cellular Microbiology.Emergency medicine international · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The activity in vitro of four types of colicins (A, E1, E3, U) against one human standard fibroblast line and against 11 human tumor-cell lines carrying defined mutations of the p53 gene was quantified by MTT (tetrazolium bromide) assay. Flow cytometry showed that the pore-forming colicins A, E1 and U affected the cell cycle of 5 of these cell lines. Colicins E3 and U did not show any distinct inhibitory effects on the cell lines, while colicins E1 and especially A inhibited the growth of all of them (with one exception concerning colicin E1). Colicin E1 inhibited the growth of the tumor lines by 17-40% and standard fibroblasts MRC5 by 11%. Colicin A exhibited a differentiated 16-56% inhibition, the growth of standard fibroblasts being inhibited by 36%. In three of the lines, colicins A and E1 increased the number of cells in the G1 phase (by 12-58%) and in apoptosis (by 7-58%). These results correlated with the data from sensitivity assays. Hence, the inhibitory effect of colicins on eukaryotic cells in cell-selective, colicin-specific and can be considered to be cytotoxic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.